World's first intra-arterial cerebral infusion of Avastin directly into a patient's malignant brain tumor

18. November 2009 04:43

Neurosurgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center performed the world's first intra-arterial cerebral infusion of Avastin (bevacizumab) directly into a patient's malignant brain tumor. This novel intra-arterial (IA) technique may expose the cancer to higher doses of the drug therapy, while possibly sparing the patient common side effects of receiving the drug intravenously (IV) or throughout their body. [More]

50d53b19-1261-4af8-9034-c4c1c09f6f70|0|.0

Posted in: Medical Procedure News | Medical Condition News

Tags: Avastin, Bevacizumab, Biopsy, Blood Vessel, Bone, Bone Marrow, Brain, Brain Cancer, Brain Tumor, Cancer, Cervical Cancer, Deep Brain Stimulation, Drug Delivery, Education, Gene Therapy, Glioblastoma, Glioblastoma Multiforme, Hospital, Neurology, Oncology, Parkinson's Disease, Penicillin, Pregnancy, Radiology, Spine

Press conference highlights emerging treatments in pancreatic cancer

18. November 2009 03:30

As part of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Thompson will moderate a press conference on emerging treatments in pancreatic cancer on Tuesday, Nov. 17, 2009, in Room 202 of the Hynes Convention Center in Boston, Mass., from 1:00 p.m. to 2:00 p.m. ET. [More]

a8f28545-1bf2-426a-9fe3-eefc360e22ae|0|.0

Posted in: Medical Condition News

Tags: Abraxane, Angiogenesis, Antibody, Avastin, Bevacizumab, Blood Vessel, Cancer, Cell, Chemotherapy, Dermatology, Gemcitabine, Gemzar, Gene Expression, Hospital, Liver Cancer, Metastasis, microRNA, Nanotechnology, Oncology, Paclitaxel, Pancreatic Cancer, Pathology, Photodynamic Therapy, Radiotherapy, VEGF

Genentech submits sBLAs to the FDA for Avastin

17. November 2009 03:36

Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the Phase III study AVADO that investigated Avastin in combination with docetaxel chemotherapy. [More]

52d6ae04-8005-4377-aa8f-72b645331f28|0|.0

Posted in: Women's Health News | Pharmaceutical News

Tags: Abdominal Pain, Angiogenesis, Anthracycline, Antibody, Avastin, Back Pain, Bevacizumab, Biotechnology, Birth Control, Blood Pressure, Blood Vessel, Bone, Brain, Breast Cancer, Cancer, Capecitabine, Cell, Chemotherapy, Congestive Heart Failure, Dehydration, Dermatitis, Diarrhea, Docetaxel, Fertility, Fistula, Headache, Heart Failure, Low Blood Pressure, Nausea, Nervous System, Paclitaxel, Pregnancy, Stroke, VEGF, Vomiting, Wound Healing

Idera Pharmaceuticals announces financial results for the third quarter of 2009

5. November 2009 07:54

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009. [More]

8ff77ca2-571a-46e3-884c-ad4815778782|0|.0

Posted in: Business / Finance

Tags: Allergy, Antisense, Arthritis, Asthma, Avastin, Bevacizumab, Bone, Cancer, Cell, Collagen, Colorectal Cancer, Cytokines, Diarrhea, DNA, Erlotinib, Etanercept, Gene Expression, Headache, Hepatitis C, Kidney Cancer, Lung Cancer, Nausea, Non-Small Cell Lung Cancer, Oligonucleotides, Oncology, Pathology, Pfizer, Potassium, Renal Cell Carcinoma, Respiratory Disease, Rheumatology, Ribavirin, Small Cell Lung Cancer, Tarceva, Vaccine, Virus

Study reveals high risk of recurrence for early-stage breast cancer patients with HER2 positive tumors

3. November 2009 03:54

Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center. [More]

eda4f03f-5cee-4957-bf23-2581e6c16eb4|0|.0

Posted in: Medical Condition News | Women's Health News

Tags: Adjuvant Therapy, Antibody, Avastin, Bevacizumab, Breast Cancer, Cancer, Chemotherapy, Education, Hospital, Monoclonal Antibody, Oncology, Pathology

Third-quarter 2009 financial results of Antigenics announced

29. October 2009 07:45

Antigenics Inc. reported today its results for the quarter ended September 30, 2009. The company incurred a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, for the third quarter of 2009, compared with a net loss attributable to common stockholders in the third quarter of 2008 of $11.4 million, or $0.17 per share, basic and diluted. [More]

beccde3b-30c7-491a-9183-553d440fa184|0|.0

Posted in: Business / Finance

Tags: Avastin, Bevacizumab, Biotechnology, Brain, Brain Tumor, Burn, Cancer, Cell, Glioblastoma, Glioma, Immunotherapy, Irinotecan, Kidney Cancer, Oncology, Radiation Therapy, Renal Cell Carcinoma, Temozolomide, Vaccine

Report on the future market potential for monoclonal antibodies

27. October 2009 08:28

Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment [More]

1390c2ed-5424-4638-98ae-15d3991e0ba3|0|.0

Posted in: Pharmaceutical News

Tags: Adalimumab, Alzheimer's Disease, Antibody, Arthritis, Avastin, Bevacizumab, Biotechnology, Cancer, Cetuximab, Crohn's Disease, Eculizumab, Evolution, Genetics, Hodgkin's Lymphoma, Infliximab, Lymphoma, Macular Degeneration, Monoclonal Antibody, Multiple Sclerosis, Non-Hodgkin's Lymphoma, Psoriasis, Ranibizumab, Raptiva, Rheumatoid Arthritis, Rituximab, Transplant, Vectibix, Zevalin

Report on immunotherapies and vaccines for nontraditional indications

27. October 2009 07:23

Reportlinker Adds Immunotherapies and Vaccines for Nontraditional Indications [More]

af658754-fc7c-4c13-ace7-e78ad0b60768|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Alzheimer's Disease, Angina, Angiotensin, Ankylosing Spondylitis, Antibody, Anti-Inflammatory, Arthritis, Atherosclerosis, Avastin, Back Pain, beta Amyloid, Bevacizumab, Biotechnology, Bone, Breast Cancer, Cancer, Cardiovascular Disease, Cell, Cholesterol, Cocaine Addiction, Colorectal Cancer, Denosumab, Diabetes, Diabetic Macular Edema, Diabetic Retinopathy, Dyslipidemia, Eculizumab, Edema, Endometriosis, Glioblastoma, Hematology, Immunotherapy, Lipids, Lung Cancer, Macular Degeneration, Metabolism, Monoclonal Antibody, Neurology, Neuropathy, Nicotine, Nicotine Addiction, Non-Small Cell Lung Cancer, Ophthalmology, Osteoporosis, Parkinson's Disease, Pfizer, Polio, Ranibizumab, Rheumatoid Arthritis, Small Cell Lung Cancer, Smoking, Smoking Cessation, Stroke, Thrombosis, Transplant, Type 2 Diabetes, Uveitis, Vaccine, VEGF

Some patients with AMD develop elevated pressure within the eye following anti-VEGF medications: Study

27. October 2009 04:14

A first-time finding of intraocular pressure increases in patients with no personal or family history of glaucoma following anti-VEGF treatment for wet age-related macular degeneration (AMD), and a report on a simple, low-cost method that could revolutionize vision screening and treatment in developing countries, are highlights of today's Scientific Program of the 2009 Joint Meeting of the American Academy of Ophthalmology (AAO) and the Pan-American Association of Ophthalmology (PAAO). [More]

45ec6c63-4fd5-4043-9ae8-1a3678c125bb|0|.0

Posted in: Medical Condition News

Tags: Bevacizumab, Blindness, Cataract, Education, Glaucoma, Macular Degeneration, Ophthalmology, Poverty, Ranibizumab, VEGF

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

26. October 2009 07:48

Antigenics today announced that the Brain Tumor Research Center at the University of California, San Francisco (UCSF), has presented an update on a Phase 2 clinical trial of Oncophage (vitespen) for recurrent high grade glioma (brain cancer) at the 2009 Joint Meeting of SNO (Society for Neuro-Oncology) and AANS/CNS Section on Tumors 2009 in New Orleans, LA. [More]

1cee8ed9-fbff-4e69-acfa-2eed69987dae|0|.0

Posted in: Drug Trial News | Pharmaceutical News

Tags: Avastin, Bevacizumab, Biotechnology, Brain, Brain Cancer, Brain Tumor, Cancer, Cell, Chemotherapy, Glioblastoma, Glioma, Immunotherapy, Irinotecan, Kidney Cancer, Lymphoma, Melanoma, Neoplasm, Oncology, Renal Cell Carcinoma, Temozolomide, Vaccine

FDA approves new oral medication for renal cell carcinoma

20. October 2009 00:15

The U.S. Food and Drug Administration today approved Votrient (pazopanib), the sixth drug to be approved for kidney cancer since 2005. [More]

30295d9f-88b8-44ff-a627-5042443eb0e9|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Abdominal Pain, Angiogenesis, Bevacizumab, Blood Pressure, Cancer, Cell, Diarrhea, Headache, Kidney Cancer, Nausea, Oncology, Pazopanib, Pregnancy, Renal Cell Carcinoma, Sorafenib, Sunitinib, Temsirolimus, Vomiting

Controlled trial comparing Bevacizumab to Ranibizumab finds no difference in efficacy

9. October 2009 11:33

Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD). [More]

042b9493-e17f-4a50-bb71-68b43aea6db5|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Avastin, Bevacizumab, Blindness, Cancer, Macular Degeneration, Ophthalmology, Ranibizumab, Veterans Affairs

Report on the various segments of cancer treatment

25. September 2009 04:28

This Kalorama Information report - The World Market for Cancer Therapeutics and Biotherapeutics - focuses on several segments for cancer treatment. The report covers both currently marketed and late stage development cancer products. Revenues for each current market segment were generated using dollar and unit sales for each product. [More]

0651d78e-34af-436d-ae14-022935085327|0|.0

Posted in: Medical Condition News

Tags: Alimta, Antisense, Apoptosis, Avastin, Bevacizumab, Biochemistry, Bladder Cancer, Breast Cancer, Cancer, Cervical Cancer, Cetuximab, Chemotherapy, Colorectal Cancer, DNA, Esophageal Cancer, Estrogen, Gemzar, Gleevec, Gonadotropin, Investment, Iressa, Leukemia, Life Expectancy, Lung Cancer, Lymphoma, MabThera, Melanoma, Metabolism, Multiple Myeloma, Neuroblastoma, Obesity, Oligonucleotides, Ovarian Cancer, Pfizer, Pharmacogenomics, Prostate Cancer, Radiation Therapy, Rituximab, Sprycel, Stomach Cancer, Tarceva, Taxol, Taxotere, Vectibix, Xeloda, Zolinza

Phase 2 trial results of Bayer's Nexavar in combination with capecitabine announced

23. September 2009 07:13

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the full results from their first collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trial showing that Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, significantly extended progression-free survival in patients with advanced breast cancer. [More]

5cc2d3f1-c2a5-43b2-bf2b-10ddd6949979|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Abdominal Pain, Adjuvant Therapy, Alopecia, Angiogenesis, Bevacizumab, Blood Pressure, Breast Cancer, Cancer, Capecitabine, Cardiology, Cell, Cell Proliferation, Chemotherapy, Colorectal Cancer, Diabetes, Diarrhea, Docetaxel, Dyspnea, Gemcitabine, Hematology, Hepatocellular Carcinoma, Kidney Cancer, Liver Cancer, Multiple Sclerosis, Nausea, Neutropenia, Nexavar, Oncology, Paclitaxel, Sorafenib, Weight Loss

Phase 1 clinical trial results evaluating ARIAD's investigational mTOR inhibitor ridaforolimus

21. September 2009 08:16

ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced data from a Phase 1 clinical trial evaluating oral ridaforolimus, its investigational mTOR inhibitor, in combination with bevacizumab (Avastin®) in heavily pretreated patients with refractory metastatic solid tumors. The data were presented at the Joint Multidisciplinary Congress of the 15th annual European Cancer Organization (ECCO) and the 34th annual European Society of Medical Oncology (ESMO) taking place in Berlin, Germany. [More]

ccd7b9cd-6501-46e4-897e-04a104a45449|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Angiogenesis, Avastin, Bevacizumab, Cancer, Cell, Kinase Inhibitor, Metabolism, Oncology, Radiotherapy, VEGF

Free!

Recent Comments

Twitter

Information

Bevacizumab News and Research

World's first intra-arterial cerebral infusion of Avastin directly into a patient's malignant brain tumor

Press conference highlights emerging treatments in pancreatic cancer

Genentech submits sBLAs to the FDA for Avastin

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Study reveals high risk of recurrence for early-stage breast cancer patients with HER2 positive tumors

Third-quarter 2009 financial results of Antigenics announced

Report on the future market potential for monoclonal antibodies

Report on immunotherapies and vaccines for nontraditional indications

Some patients with AMD develop elevated pressure within the eye following anti-VEGF medications: Study

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

FDA approves new oral medication for renal cell carcinoma

Controlled trial comparing Bevacizumab to Ranibizumab finds no difference in efficacy

Report on the various segments of cancer treatment

Phase 2 trial results of Bayer's Nexavar in combination with capecitabine announced

Phase 1 clinical trial results evaluating ARIAD's investigational mTOR inhibitor ridaforolimus

Recent Articles

Free!

Recent Comments

Twitter

Information

Bevacizumab News and Research

Medical News Cloud

Recent Articles